It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores. What are ...

Core Viewpoint - HealthEquity (HQY) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which have a strong correlation with near-term stock price movements [4][6]. - Rising earnings estimates for HealthEquity suggest an improvement in the company's underlying business, likely leading to increased stock prices [5][10]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with a proven track record of performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7][9]. - Only the top 20% of Zacks-covered stocks receive a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions [10]. HealthEquity's Earnings Estimates - HealthEquity is expected to earn $3.73 per share for the fiscal year ending January 2026, with no year-over-year change [8]. - Over the past three months, the Zacks Consensus Estimate for HealthEquity has increased by 8.8%, reflecting analysts' positive revisions [8].

Core Insights - The article compares GoodRx Holdings, Inc. (GDRX) and HealthEquity (HQY) to determine which stock is more attractive to value investors [1] - GDRX has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while HQY has a Zacks Rank of 3 (Hold) [3] Valuation Metrics - GDRX has a forward P/E ratio of 12.80, significantly lower than HQY's forward P/E of 27.57 [5] - The PEG ratio for GDRX is 1.15, while HQY's PEG ratio is 1.32, suggesting GDRX is more favorably valued considering expected earnings growth [5] - GDRX's P/B ratio is 2.64 compared to HQY's P/B of 4.2, further indicating GDRX's relative undervaluation [6] Value Grades - GDRX has earned a Value grade of B, while HQY has a Value grade of D, highlighting GDRX's superior valuation metrics [6] - The combination of solid earnings outlook and favorable valuation figures positions GDRX as the better value option currently [6]

Core Viewpoint - HealthEquity (HQY) shares have declined approximately 10.4% over the past month, underperforming the S&P 500, raising questions about the potential for a breakout or continued negative trend leading up to the next earnings release [1] Group 1: Earnings Report and Estimates - The consensus estimate for HealthEquity has increased by 8.01% over the past month, indicating a positive trend in estimates [2] - The stock has received a Zacks Rank 2 (Buy), suggesting expectations for above-average returns in the coming months [4] Group 2: VGM Scores - HealthEquity has a Growth Score of B and a Momentum Score of B, indicating strong performance in these areas [3] - The stock has a Value Score of C, placing it in the middle 20% for this investment strategy, contributing to an overall aggregate VGM Score of B [3]

Core Viewpoint - Growth investors are attracted to stocks with above-average financial growth, but identifying such stocks can be challenging due to inherent risks and volatility [1] Group 1: Company Overview - HealthEquity (HQY) is identified as a promising growth stock, supported by a favorable Growth Score and a top Zacks Rank [2] - The company provides services for managing health care accounts, making it a relevant choice for growth investors [3] Group 2: Earnings Growth - HealthEquity has a historical EPS growth rate of 19.1%, with projected EPS growth of 19.3% for the current year, significantly outperforming the industry average of 8.5% [5] Group 3: Cash Flow Growth - The year-over-year cash flow growth for HealthEquity stands at 25.9%, well above the industry average of -1.5% [6] - The company's annualized cash flow growth rate over the past 3-5 years is 19.3%, compared to the industry average of 7.6% [7] Group 4: Earnings Estimate Revisions - There has been a positive trend in earnings estimate revisions for HealthEquity, with the Zacks Consensus Estimate for the current year increasing by 9.2% over the past month [8] Group 5: Investment Potential - HealthEquity holds a Zacks Rank of 2 (Buy) and a Growth Score of B, indicating its potential as an outperformer and a solid choice for growth investors [10]

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth stock that can live up to its true potential can be a tough task.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, it's pretty easy to find cutting-edge growth stocks wit ...

Core Insights - HealthEquity, Inc. reported better-than-expected first-quarter results with earnings of 97 cents per share, surpassing the consensus estimate of 88 cents [1] - Quarterly revenue reached $330.8 million, exceeding the Street estimate of $321.17 million [1] Financial Performance - The company achieved record quarterly revenue and record Adjusted EBITDA in the first quarter of fiscal 2026 [2] - HealthEquity raised its fiscal 2026 adjusted EPS guidance to a new range of $3.61 to $3.78, compared to the previous range of $3.57 to $3.74 and the analyst estimate of $3.63 [2] - The revenue outlook for fiscal 2026 remains between $1.28 billion and $1.3 billion, aligning with the $1.3 billion estimate [2] Stock Market Reaction - Following the earnings announcement, HealthEquity shares increased by 9.8% to $113.94 [3] - Analysts adjusted their price targets for HealthEquity after the earnings report [3] Analyst Ratings and Price Targets - JMP Securities analyst maintained a Market Outperform rating and raised the price target from $110 to $117 [5] - B of A Securities analyst maintained a Buy rating and increased the price target from $110 to $125 [5] - RBC Capital analyst maintained an Outperform rating and raised the price target from $112 to $117 [5] - Goldman Sachs analyst maintained a Neutral rating and increased the price target from $94 to $104 [5]

Core Insights - HealthEquity, Inc. (HQY) reported adjusted earnings per share (EPS) of 97 cents for the first quarter of fiscal 2026, exceeding the Zacks Consensus Estimate by 19.8% and showing a year-over-year improvement of 21.3% [2][10] - The company generated revenues of $330.8 million in the fiscal first quarter, surpassing the Zacks Consensus Estimate by 3% and reflecting a 15% increase from the prior-year quarter [3][10] - HealthEquity's total number of Health Savings Accounts (HSAs) reached 9.9 million, a 9% year-over-year increase, with total HSA assets amounting to $31.3 billion, up 15% year over year [4][5] Revenue Breakdown - Service revenues for the quarter totaled $119.8 million, up 1.3% year over year, driven by an increase in HSAs and invested HSA assets [7] - Custodial revenues reached $156.5 million, marking a 28.6% increase from the previous year, while interchange revenues totaled $54.6 million, up 14.4% year over year [8][10] Margin and Profitability - HealthEquity's gross profit rose 19.9% to $224.3 million, with the gross margin expanding by 270 basis points to 67.8% [11][10] - Operating profit improved significantly by 99.6% to $83.1 million, with the operating margin expanding by 1060 basis points to 25.1% [13][10] Financial Position - At the end of the first quarter of fiscal 2026, HealthEquity had cash and cash equivalents of $287.9 million and total debt of $1.06 billion, unchanged from the previous quarter [14] - Net cash provided by operating activities was $64.7 million, slightly down from $65.4 million a year ago [14] Guidance and Future Outlook - HealthEquity has reiterated its revenue guidance for fiscal 2026, projecting revenues between $1.285 billion and $1.305 billion, with adjusted EPS expected in the range of $3.61-$3.78 [15] - The company added 150,000 new HSAs during the quarter and reported a significant reduction in fraud-related costs, which dropped from $11 million to $3 million, enhancing margins and member trust [17][18]

Core Viewpoint - HealthEquity (NASDAQ: HQY) has shown strong performance over the past year, with a 28% increase in share value, driven by growth in health savings accounts (HSAs) and sustained high interest rates [1] Company Performance - The company's shares have continued to perform well, indicating positive market sentiment and investor confidence [1] Market Trends - The growth in health savings accounts (HSAs) is a significant factor contributing to the company's success, reflecting broader trends in the healthcare and financial sectors [1] - Higher interest rates have also played a role in enhancing the company's financial performance, suggesting a favorable economic environment for HealthEquity [1]

HealthEquity (HQY) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.80 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 19.75%. A quarter ago, it was expected that this provider of services for managing health care accounts would post earnings of $0.71 per share when it actually produced earnings of $0.69, delivering a surprise of -2.82 ...